Previous 10 | Next 10 |
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate at the following upcoming investor conferences: Goldman Sachs 40 th Annual Global Healthcare Conference at 2:00 p.m. PT (5:00 p.m. ET) on June 12, 2019 in Rancho Palos Verdes, CA. ...
CIRCOR (NYSE: CIR ) +51% on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX). For many years, the Company, (formerly Impax ...
Endpoints News reports that Gilead Sciences ( GILD +1.6% ) CEO Daniel O'Day spent more than three hours yesterday trying to justify the $2,000/month price of Truvada (emtricitabine and tenofovir disoproxil fumarate) before a U.S. House committee on oversight and reform. The FDA approved ...
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m. Eastern Time. To access a live webcast of the presentation, v...
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2019 Earnings Conference Call May 09, 2019 8:30 AM ET Company Participants Mark Donohue – Vice President of Investor Relations and Corporate Communications Rob Stewart – President and Chief Executive Officer Todd Branning ...
Amneal Pharmaceuticals ( AMRX -16.1% ) Q1 results : Revenues: $446.1M (+62.1%). More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Amneal Pharmaceuticals (NYSE: AMRX ): Q1 Non-GAAP EPS of $0.14 misses by $0.04 ; GAAP EPS of -$0.37. More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
‒ Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Continued Progress in Diversifying Portfolio and Optimizing Business ‒ ‒ Reaffirming Full Year 2019 Financial Guidance ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...